PharmaVoice Logo

Healthcare Leaders Hub

Merck’s Sacituzumab Tirumotecan (Sac-TMT) Meets Primary Endpoint of Overall Survival in P-III TroFuse-015 Trial for Gastroesophageal Adenocarcinoma | PharmaVoice